Literature DB >> 10523851

gamma-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line.

X Z Wang1, E M Jolicoeur, N Conte, M Chaffanet, Y Zhang, M J Mozziconacci, H Feiner, D Birnbaum, M J Pébusque, D Ron.   

Abstract

gamma-heregulin is a recently described novel isoform of the heregulin/neuregulin class of EGF-like ligands that bind to and activate receptors of the ErbB family. Deregulated signaling through the heregulin-ErbB pathway is thought to be implicated in the development of a subset of human breast cancers. gamma-heregulin has been found to be expressed in the culture supernatant of MDA-MB-175, a breast carcinoma cell line. gamma-heregulin is characterized by the presence of a large N-terminal peptide extension that is not found in other heregulin isoforms. Here we report that this unique N-terminal extension of gamma-heregulin is identical to the N-terminus of DOC4, a product of a recently identified CHOP-dependent stress-induced gene. Human DOC4 and the heregulin-encoding genes map to different chromosomes and the MDA-MB-175 cell line contains a chromosomal translocation that leads to the fusion of DOC4 and HGL, on chromosomes 11 and 8, respectively. Thus, gamma-heregulin is a product of a mutant fusion gene and not a bona fide normal isoform. We speculate that the mutation may be selected for by virtue of its ability to activate ErbB signaling through the production of an autocrine ligand.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523851     DOI: 10.1038/sj.onc.1202950

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

Review 1.  ErbB-4: a receptor tyrosine kinase.

Authors:  W Zhou; G Carpenter
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

Review 2.  Signalling between microvascular endothelium and cardiomyocytes through neuregulin.

Authors:  Emily M Parodi; Bernhard Kuhn
Journal:  Cardiovasc Res       Date:  2014-01-29       Impact factor: 10.787

Review 3.  Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network.

Authors:  K L Troyer; D C Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

Review 4.  Roles for neuregulins in human cancer.

Authors:  Christophe Stove; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.

Authors:  Alison M Schram; Igor Odintsov; Madelyn Espinosa-Cotton; Inna Khodos; Whitney J Sisso; Marissa S Mattar; Allan J W Lui; Morana Vojnic; Sara H Shameem; Thrusha Chauhan; Jean Torrisi; Jim Ford; Marie N O'Connor; Cecile A W Geuijen; Ron C J Schackmann; Jeroen J Lammerts van Bueren; Ernesto Wasserman; Elisa de Stanchina; Eileen M O'Reilly; Marc Ladanyi; Alexander Drilon; Romel Somwar
Journal:  Cancer Discov       Date:  2022-05-02       Impact factor: 38.272

6.  The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions.

Authors:  Igor Odintsov; Allan J W Lui; Whitney J Sisso; Eric Gladstone; Zebing Liu; Lukas Delasos; Renate I Kurth; Exequiel M Sisso; Morana Vojnic; Inna Khodos; Marissa S Mattar; Elisa de Stanchina; Shawn M Leland; Marc Ladanyi; Romel Somwar
Journal:  Clin Cancer Res       Date:  2021-04-06       Impact factor: 12.531

7.  Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.

Authors:  Igor Odintsov; Marissa S Mattar; Allan J W Lui; Michael Offin; Christopher Kurzatkowski; Lukas Delasos; Inna Khodos; Marina Asher; Robert M Daly; Natasha Rekhtman; Elisa de Stanchina; Gopinath Ganji; Marc Ladanyi; Romel Somwar
Journal:  J Thorac Oncol       Date:  2021-04-08       Impact factor: 20.121

8.  Molecular cytogenetic analysis of breast cancer cell lines.

Authors:  J M Davidson; K L Gorringe; S F Chin; B Orsetti; C Besret; C Courtay-Cahen; I Roberts; C Theillet; C Caldas; P A Edwards
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

9.  The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene.

Authors:  Y L Chua; Y Ito; J C M Pole; S Newman; S-F Chin; R C Stein; I O Ellis; C Caldas; M J O'Hare; A Murrell; P A W Edwards
Journal:  Oncogene       Date:  2009-10-05       Impact factor: 9.867

10.  Array painting reveals a high frequency of balanced translocations in breast cancer cell lines that break in cancer-relevant genes.

Authors:  K D Howarth; K A Blood; B L Ng; J C Beavis; Y Chua; S L Cooke; S Raby; K Ichimura; V P Collins; N P Carter; P A W Edwards
Journal:  Oncogene       Date:  2007-12-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.